aside from taking Celgene into the field of multiple sclerosis with oral drug ozanimod, the compound could become an important new drug in ulcerative colitis. Ozanimod is an oral medicine and ...

Celgene's drug Otezla (apremilast) is an oral, selective inhibitor of phosphodiesterase 4 (PDE4) and gained its first approval in March this year for the treatment of psoriatic arthritis.

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts before President-elect Trump’s inauguration. The Centers for Medicare and ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund.

As LB Pharmaceuticals enters a pivotal stage of growth, the additions of Gad and Richard to our leadership team reinforce our ability to execute on our ambitious clinical and regulatory goals,” said ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

In this piece, we will look at the stocks Jim Cramer recently discussed.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal ...

Revlimid, the big-selling multiple myeloma drug acquired in Bristol’s buyout of Celgene, will face a new slate of generics in March and then a full generic market in 2026, Boerner said.